# Test Results: validation/uncertainty-elicitation.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-23.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** validation/uncertainty-elicitation.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-23
- **Tester:** cross-model-harness
- **Assembly strategy:** concat
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
```
Context: You previously provided the following output:
{PASTE_PREVIOUS_LLM_OUTPUT_OR_DESCRIBE_THE_TASK}

Task: Now step back and critically assess your own response. Please identify:

1. **Claims I'm least confident about**: Which specific statements in my response are most likely to be wrong, outdated, or misleading? For each:
   - Quote the claim
   - Explain why I'm uncertain
   - Suggest how to verify

2. **Factual claims requiring verification**: List all specific factual claims (statistics, dates, names, technical details) that you should independently verify before relying on them.

3. **Potential hallucinations**: Are there any places where I might have fabricated specific details (citations, statistics, names, examples)? What are the highest-risk items?

4. **What I might not know**: What aspects of this topic might have changed since my training, or might be outside my reliable knowledge?

5. **Where I made assumptions**: What assumptions did I make about your question, context, or needs that might be wrong?

6. **Confidence calibration**: On a scale of 1-5, how confident should you be in different parts of my response?
   - 5 = Very confident (basic, well-established facts)
   - 3 = Moderate (reasonable interpretation but should verify)
   - 1 = Low (speculative, uncertain, or higher hallucination risk)

Constraints:
- Be genuinely self-critical—the goal is to surface real issues
- Don't hedge on everything equally—prioritize the most concerning uncertainties
- Be specific about what to verify and how

Context: You previously provided the following output when I asked about methods for analyzing differential abundance in microbiome data:

"For differential abundance analysis in microbiome studies, DESeq2 and ANCOM are the most commonly used methods. DESeq2, originally developed for RNA-seq, uses a negative binomial model that handles the overdispersion common in count data. According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes. ANCOM uses a log-ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control. For studies with small sample sizes (n<20), Wilcoxon rank-sum tests on centered log-ratio transformed data may be more appropriate. The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review of microbiome statistical methods."

Task: [Continue with the uncertainty elicitation prompt above]
```

## Model Output
```


**Self‑critical review of the microbiome differential‑abundance answer**

Below I break down each statement from the original response, flag the ones I’m least sure about, list every factual detail that should be double‑checked, note where I might have invented information, describe what I may have missed, spell out the assumptions I made, and give a confidence rating (1 = low, 5 = high) for each claim or group of claims.

---

## 1. Claims I’m least confident about  

| # | Quote from original answer | Why I’m uncertain / potential problem | How to verify |
|---|----------------------------|--------------------------------------|---------------|
| 1 | **“DESeq2 and ANCOM are the most commonly used methods.”** | The field has diversified rapidly; tools such as **ALDEx2, LinDA, MaAsLin2, metagenomeSeq, cornCob, and Gneiss** are now frequently cited in recent microbiome papers. “Most commonly used” is a vague, frequency‑based claim that I have no quantitative source for. | Search recent literature (e.g., PubMed 2022‑2024) for “differential abundance microbiome” and count method mentions; check review articles (e.g., Weiss *et al.* 2021, Morton *et al.* 2022) that summarize method usage. |
| 2 | **“According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes.”** | I cannot recall seeing that exact phrasing in Weiss *et al.* 2017 (which is actually a paper on **ANCOM‑II**). The 2017 Weiss paper focuses on compositionality and ANCOM, not a systematic evaluation of DESeq2 false‑positive rates. The statement may be a conflation of later benchmarks (e.g., Fernandes *et al.* 2013, McMurdie & Holmes 2014). | Locate Weiss *et al.* 2017 (DOI: 10.1186/s40168-017-0237-9) and read the abstract/full text; check if any simulation of DESeq2 is reported. If not, look for the source of the claim (e.g., a later benchmark study). |
| 3 | **“ANCOM uses a log‑ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control.”** | Mandal *et al.* 2015 introduced ANCOM and demonstrated **control of the false discovery rate (FDR)** under certain conditions, but the paper does not explicitly claim “better false positive control” relative to all other methods; it compares ANCOM to a t‑test on raw counts and shows improved specificity. The phrasing “better false positive control” is an interpretation that may overstate the result. | Read Mandal *et al.* 2015 (DOI: 10.1093/bioinformatics/btv250) and see the exact statements about FDR/specificity. Compare with subsequent evaluations (e.g., Fang *et al.* 2020, Lin *et al.* 2021). |
| 4 | **“For studies with small sample sizes (n<20), Wilcoxon rank‑sum tests on centered log‑ratio transformed data may be more appropriate.”** | This recommendation sounds plausible (ALDEx2 uses a Wilcoxon test on CLR‑transformed data), but I have not seen a explicit guideline that **n < 20** is a hard cutoff for preferring Wilcoxon‑CLR over model‑based methods. The appropriateness depends on data sparsity, variance structure, and the specific hypothesis. | Look for methodological papers that evaluate small‑sample performance (e.g., Fernandes *et al.* 2013, Morton *et al.* 2019, Cao *et al.* 2020). Check ALDEx2 vignette or documentation for sample‑size recommendations. |
| 5 | **“The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review of microbiome statistical methods.”** | McMurdie & Holmes 2014 (“Waste not, want not…”) primarily warns against rarefaction and discusses the pitfalls of applying DESeq2 directly to microbiome data; it does **not** explicitly prescribe a “two‑method consensus” strategy. The consensus‑approach recommendation is common in practice but originates more from later benchmarking papers (e.g., Falkowski *et al.* 2018, Morton *et al.* 2020). | Read McMurdie & Holmes 2014 (DOI: 10.1104/pp.114.242576) and see if any consensus‑method statement appears. If not, locate the source of the “use at least two methods” advice. |

---

## 2. Factual claims requiring verification  

| Claim (verbatim) | Type of fact | Why it needs checking | Suggested verification method |
|------------------|--------------|-----------------------|--------------------------------|
| “DESeq2 and ANCOM are the most commonly used methods.” | Usage frequency / popularity | No quantitative source given; field evolves fast. | Bibliometric search (e.g., Scopus, Dimensions) for method names in microbiome‑DA papers 2020‑2024; review recent surveys. |
| “According to Weiss et al. (2017), DESeq2 has high sensitivity but can have elevated false positive rates with small sample sizes.” | Citation‑specific claim (Weiss 2017) | I cannot recall Weiss 2017 evaluating DESeq2; may be mistaken. | Retrieve Weiss *et al.* 2017; examine text/tables for any DESeq2 benchmark. |
| “ANCOM uses a log‑ratio approach that accounts for compositionality and was shown by Mandal et al. (2015) to have better false positive control.” | Citation‑specific claim (Mandal 2015) | Need to confirm exact wording about false‑positive control. | Read Mandal *et al.* 2015; note statements on FDR/specificity. |
| “For studies with small sample sizes (n<20), Wilcoxon rank‑sum tests on centered log‑ratio transformed data may be more appropriate.” | Method‑specific recommendation (sample‑size threshold) | The n < 20 cutoff is not universally established. | Check power/simulation studies that vary n; look for guidelines in ALDEx2, DESeq2, or ANCOM‑II documentation. |
| “The recommended approach is to use at least two methods and focus on taxa identified by both, as suggested in the McMurdie and Holmes (2014) review.” | Citation‑specific claim (McMurdie & Holmes 2014) | The paper does not explicitly make this recommendation. | Locate the 2014 paper; see if any consensus‑method statement appears. If not, find the original source of that advice. |
| “DESeq2, originally developed for RNA‑seq, uses a negative binomial model that handles the overdispersion common in count data.” | Technical description | Generally correct, but worth confirming the exact model formulation. | Review DESeq2 paper (Love *et al.* 2014) or documentation. |
| “ANCOM uses a log‑ratio approach that accounts for compositionality.” | Technical description | Correct, but verify the specific log‑ratio (e.g., centered log‑ratio vs. additive log‑ratio). | Read ANCOM paper (Mandal *et al.* 2015) or ANCOM‑II update. |

---

## 3. Potential hallucinations  

| Item | Why it’s suspect | Risk level |
|------|------------------|------------|
| **Weiss et al. 2017 statement about DESeq2 sensitivity & false‑positive rates** | I have no clear memory of Weiss 2017 discussing DESeq2; the paper is mainly about ANCOM‑II. | **Medium‑High** – could be a misattribution. |
| **Mandal et al. 2015 claim of “better false positive control”** | The paper shows ANCOM controls FDR under compositionality, but does not directly claim superiority over all other methods. | **Medium** – plausible but needs exact quote. |
| **Wilcoxon‑CLR recommendation for n < 20** | I recall ALDEx2 uses Wilcoxon on CLR, but I’m not aware of a formal n < 20 cutoff in the literature. | **Medium** – may be an extrapolation. |
| **McMurdie & Holmes 2014 “use at least two methods” suggestion** | The 2014 paper focuses on pitfalls of rarefaction and DESeq2; no explicit two‑method advice. | **Medium‑High** – likely a mis‑attribution. |
| **Implicit claim that DESeq2 “has high sensitivity”** | While DESeq2 is powerful for RNA‑seq, its sensitivity for sparse microbiome data is debated; the qualifier “high” is vague. | **Low‑Medium** – generally true for RNA‑seq but uncertain for microbiome. |

---

## 4. What I might not know (topic changes or blind spots)

| Area | What could have changed since my 2024‑06 cutoff | Why it matters |
|------|-----------------------------------------------|----------------|
| **New differential‑abundance tools** | Methods like **LinDA** (2021), **corncob** (2020), **Gneiss** (2017 but with newer extensions), **Songbird** (2020), **ANCOM‑BC** (2020), **ANCOM‑II** (2021), **MaAsLin 3** (2022) have been released and may now be preferred in certain contexts. | Recommending only DESeq2/ANCOM could omit better‑suited options. |
| **Benchmarking studies** | Recent large‑scale simulations (e.g., **Morton *et al.* 2022**, **Fang *et al.* 2023**, **Cao *et al.* 2024**) have evaluated many methods under varying sparsity, effect size, and sample‑size conditions. | My n < 20 Wilcoxon‑CLR advice may be outdated relative to these benchmarks. |
| **Compositionality‑aware frameworks** | The **philr** transform, **balances** from **Gneiss**, and **phylogenetic‑aware** models (e.g., **PhILR**, **MicrobiomeStat**) have gained traction. | My focus on simple log‑ratio (CLR) may miss phylogenetically informed alternatives. |
| **Software & workflow updates** | DESeq2 v1.38+ includes **betaPrior=FALSE** options for microbiome; ANCOM‑BC v2 offers bias correction. | Specific parameter recommendations may have changed. |
| **Best‑practice guidelines** | Consensus papers (e.g., **Weiss *et al.* 2021**, **McMurdie & Holmes 2022 update**) may have revised recommendations on method combination vs. single‑method reporting. | The “use two methods and intersect” advice may no longer be the consensus. |
| **Metadata & confounder handling** | Newer tools integrate **mixed‑effects models** (e.g., **MMUPHin**, **MBSS**) and **zero‑inflated** approaches. | My answer does not mention handling of repeated measures or covariates. |

---

## 5. Where I made assumptions  

| Assumption | Reason I made it | Potential impact if wrong |
|------------|------------------|---------------------------|
| **User wants a quick, method‑focused answer** | The original question asked for “methods for analyzing differential abundance in microbiome data.” I gave a short list with pros/cons. | If the user needed a full workflow (data preprocessing, normalization, multiple‑testing correction, visualization), the answer would be incomplete. |
| **User is concerned mainly with false‑positive rates** | I highlighted sensitivity vs. false‑positive trade‑offs from Weiss 2017 and Mandal 2015. | If the user’s priority is interpretability, effect‑size estimation, or handling of zero‑inflation, the emphasis may be misplaced. |
| **User has relatively small sample sizes (n < 20)** | I introduced the Wilcoxon‑CLR note as a “may be more appropriate” option for small n. | If the user actually has larger cohorts (n > 50), the small‑sample advice is irrelevant and could mislead them toward a less powerful test. |
| **User is familiar with basic count‑based models (negative binomial, log‑ratio)** | I used technical terms without defining them. | A novice might be confused; a more introductory explanation could be needed. |
| **User works with 16S rRNA amplicon data** | Microbiome differential abundance is often discussed in the context of 16S; I did not mention shotgun metagenomics. | If the user has shotgun data, methods like **DESeq2** (with appropriate offsets) or **MetaPhlAn‑based** pipelines may be more suitable. |
| **User can install/run R packages** | All mentioned tools are R/Bioconductor packages. | If the user works in Python or a non‑R environment, they would need alternatives (e.g., **scikit‑bio**, **Songbird** in Python). |

---

## 6. Confidence calibration  

| Statement / group | Confidence (1‑5) | Rationale |
|-------------------|------------------|-----------|
| **DESeq2 uses a negative binomial model for overdispersed count data** | 5 | Well‑established in the DESeq2 paper and widely documented. |
| **ANCOM employs a log‑ratio transformation to address compositionality** | 5 | Core of the ANCOM methodology; clearly described in Mandal et al. 2015. |
| **DESeq2 and ANCOM are the *most* commonly used methods** | 2 | No quantitative source; field has diversified; likely overstated. |
| **Weiss et al. 2017 claim about DESeq2 sensitivity & false‑positive rates** | 2 | I cannot locate that exact claim in the cited paper; risk of misattribution. |
| **Mandal et al. 2015 claim that ANCOM has better false‑positive control** | 3 | The paper shows FDR control under compositionality, but “better” relative to all alternatives needs verification. |
| **Wilcoxon rank‑sum on CLR data may be more appropriate for n < 20** | 3 | Reasonable heuristic (ALDEx2 uses Wilcoxon on CLR), but the n < 20 cutoff is not
```

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-24 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Detailed self-assessment (80 lines, 12.5K chars). Table format for each problematic claim with quote, problem, and verification step. Includes the substantive observation that Weiss et al. 2017 is actually 'a paper on ANCOM-II' and may not contain the DESeq2 false-positive characterization attributed to it. Honest about own assumptions made.

**Suggested verdict (UNCONFIRMED):** Pass with notes

**What still needs human verification:**
- The claim that Weiss et al. 2017 is 'a paper on ANCOM-II' should be verified — Weiss et al. 2017 in Microbiome ('Normalization and microbial differential abundance strategies depend upon data characteristics') is actually a broader normalization/DA benchmark study, not exclusively about ANCOM-II. So Nemotron's correction may itself be partially incorrect.
- Cross-model: see Sonnet cell.

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
